Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acidLEVY, C; PETER, J. A; LINDOR, K et al.Alimentary pharmacology & therapeutics. 2011, Vol 33, Num 2, pp 235-242, issn 0269-2813, 8 p.Article

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitisIMAM, M. H; SINAKOS, E; PETZ, J et al.Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 10, pp 1185-1192, issn 0269-2813, 8 p.Article

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisANGULO, P; KEACH, J. C; BATTS, K. P et al.Hepatology (Baltimore, Md.). 1999, Vol 30, Num 6, pp 1356-1362, issn 0270-9139Article

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot studyTABIBIAN, J. H; WEEDING, E; JORGENSEN, R. A et al.Alimentary pharmacology & therapeutics. 2013, Vol 37, Num 6, pp 604-612, issn 0269-2813, 9 p.Article

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acidANGULO, P; JORGENSEN, R. A; KEACH, J. C et al.Hepatology (Baltimore, Md.). 2000, Vol 31, Num 2, pp 318-323, issn 0270-9139Article

The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis ― a pilot studyMARTIN, C. R; BLANCO, P. G; LINDOR, K. D et al.Alimentary pharmacology & therapeutics. 2012, Vol 35, Num 2, pp 255-265, issn 0269-2813, 11 p.Article